Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia
Tibor Kovacsovics(Hôpital Edouard Herriot), Paul J. Shami(University of Utah), Alice S. Mims(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Linda M. Bavisotto, Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Peter Ahorukomeye(University of Utah), Ken M. Kosak(University of Utah), Jeremy Pantin(National Institutes of Health), Kenneth M. Boucher(University of Utah), Thomas P. Kennedy(Wake Forest University), Narayanam V. Rao(University of Utah), Stephen Marcus(Fort Worth Library), Michael W. Deininger(Versiti Blood Center of Wisconsin), Martha Glenn(Huntsman Cancer Institute), Gerardo Gutiérrez‐Sánchez(University of Georgia)
Cited by 59
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
|Cancer Cell|2017|619
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547
Spectrum of Epithelial Neoplasms in End-Stage Renal Disease
|The American Journal of Surgical Pathology|2006|484